ScholarMate
English简体中文繁體中文
Customer service: 400-1616-289
Sign inSign up
Journal article

DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden

Huang, Hao; Cao, Weifan; Long, Zhiping; Kuang, Lei; Li, Xi; Feng, Yifei; Wu, Yuying; Zhao, Yang; Chen, Yinggang; Sun, Peng; Peng, Panxin; Zhang, Jinli; Yuan, Lijun; Li, Tianze; Hu, Huifang; Li, Gairui; Yang, Longkun; Zhang, Xing; Hu, Fulan*; Sun, Xizhuo*; Hu, Dongsheng*哈尔滨医科大学; 中国医学科学院; 中国医学科学院北京协和医院
Frontiers in Oncology2023-1-13DOI: 10.3389/fonc.2022.1030335
2Cited by8Reads
CiteSave
Share

Abstract

BackgroundImmune checkpoint inhibitor (ICI) therapy has proven to be a promising treatment for colorectal cancer (CRC). We aim to investigate the relationship between DNA methylation and tumor mutation burden (TMB) by integrating genomic and epigenetic profiles to precisely identify clinical benefit populations and to evaluate the effect of ICI therapy. MethodsA total of 536 CRC tissues from the Cancer Genome Atlas (TCGA) with mutation data were collected and subjected to calculate TMB. 80 CRC patients with high TMB and paired normal tissues were selected as training sets and developed the diagnostic and prognostic methylation models, respectively. In the validation set, the diagnostic model was validated in our in-house 47 CRC tissues and 122 CRC tissues from the Gene Expression Omnibus (GEO) datasets, respectively. And a total of 38 CRC tissues with high TMB from the COLONOMICS dataset verified the prognostic model. ResultsA positive correlation between differential methylation positions and TMB level was observed in TCGA CRC cohort (r=0.45). The diagnostic score that consisted of methylation levels of four genes (ADHFE1, DOK6, GPR75, and MAP3K14-AS1) showed high diagnostic performance in the discovery (AUC=1.000) and two independent validation (AUC=0.946, AUC=0.857) datasets. Additionally, these four genes showed significant positive correlations with NK cells. The prognostic score containing three genes (POU3F3, SYN2, and TMEM178A) had significantly poorer survival in the high-risk TMB samples than those in the low-risk TMB samples (P=0.016). CRC patients with low-risk scores combined with TMB levels represent a favorable survival. ConclusionsBy integrating analyses of methylation and mutation data, it is suggested that DNA methylation patterns combined with TMB serve as a novel potential biomarker for early screening in more high-TMB populations and for evaluating the prognostic effect of CRC patients with ICI therapy.

Disciplines and keywords

Keywords
TMBDNA methylationcolorectal cancerimmunotherapyTCGA
Related
Loading…
  • Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
    Liu, Chao; Xiao, Huiting; Cui, Luying; Fang, Lin; Han, Shuling; Ruan, Yuli; Zhao, Wenyuan*; Zhang, Yanqiao*Frontiers in Immunology, 2022, 13: 1039631.
  • Risk scoring based on DNA methylation-driven related DEGs for colorectal cancer prognosis with systematic insights
    Liu, Zhe; Georgakopoulos-Soares, Ilias; Ahituv, Nadav; Wong, Ka-Chun*Life Sciences, 2023, 316: 121413.Cited by 2
  • Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
    Lin, Anqi; Yao, Jiarong; Cheng, Quan; Liu, Zaoqu; Luo, Peng*; Zhang, Jian*Journal of Inflammation Research, 2023, 16: 1693-1709.Cited by 1
View all →

Publication info

Publication status
Published
Journal
Frontiers in Oncology
Publication date
2023-01-13
Volume / issue
Vol. 12
Pages
1030335
DOI
10.3389/fonc.2022.1030335
Output indexing
SCIE
Funding acknowledgment
Shenzhen Key Medical Discipline Construction Fund [SZXK062]; Natural Science Foundation of China [81302483]; Science and Technology Development Foundation of Shenzhen [JCYJ20190808111817192, JCYJ20210324093807020]; Scientific Research Initiation foundation for young teachers of Shenzhen University [2019123, QNJS0160]

Authors

  • H

    Huang, Hao (First author)

    shenzhen univ

  • C

    Cao, Weifan

    shenzhen univ

View all 21 authorsShow fewer authors
  • L

    Long, Zhiping

    harbin med univ

  • K

    Kuang, Lei

    shenzhen univ

  • L

    Li, Xi

    shenzhen univ

  • F

    Feng, Yifei

    shenzhen univ

  • W

    Wu, Yuying

    shenzhen univ

  • Z

    Zhao, Yang

    shenzhen univ

  • C

    Chen, Yinggang

    chinese acad med sci · peking union med coll

  • S

    Sun, Peng

    chinese acad med sci · peking union med coll

  • P

    Peng, Panxin

    chinese acad med sci · peking union med coll

  • Z

    Zhang, Jinli

    shenzhen univ

  • Y

    Yuan, Lijun

    shenzhen univ

  • L

    Li, Tianze

    shenzhen univ

  • H

    Hu, Huifang

    shenzhen univ

  • L

    Li, Gairui

    shenzhen nanshan ctr chron dis control

  • Y

    Yang, Longkun

    fujian med univ

  • Z

    Zhang, Xing

    fujian med univ

  • H

    Hu, Fulan (Corresponding)

    shenzhen univ

  • S

    Sun, Xizhuo (Corresponding)

    shenzhen univ

  • H

    Hu, Dongsheng (Corresponding)

    shenzhen univ

Sign in for more features

  • Save this paper in My collections
  • Claim your outputs and generate promotion materials
  • Follow authors for new outputs
  • Join groups and collaborate
Sign up / Sign in

Products

  • ScholarMate
  • InnoCity
  • IRISaaS

Support

  • Help Center
  • Privacy Policy
  • Terms of Service

Contact

Online support: []
Customer service: 400-1616-289
Email: support@scholarmate.com

Follow or download ScholarMate

WeChat QR code
WeChat official account
App download QR code
Download the app
OutputsResearchersResearch institutionsResearch newsIRISaaS

©2026 深圳市科研之友网络服务有限公司

Public security registration badge粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417